Fig. 4.

In vivo specificity of SeCF₃-IRD800. (a) NIR-II imaging at different time points of intravenous injection SeCF₃-IRD800 in HepG2-Luc and HCCLM3 subcutaneous xenograft tumor models (n = 12) and HepG2-Luc subcutaneous tumor blocking experiments (n = 6). (b) Fluorescence intensity of tumor. Imaging HepG2 group (15,029.12 ± 1841.44), Imaging HCCLM3 group (11,216.16 ± 975.70), and Blocking HepG2 group (5542.80 ± 1452.13) (∗∗∗p < 0.001, Student's t-test). (c) Tumor-to-background ratio (TBR) of NIR-II fluorescence signal intensity and the skin fluorescence signal intensity around the tumor were selected as the background. Imaging HepG2 group, Imaging HCCLM3 group, and Blocking HepG2 group were determined as 4.55 ± 0.49, 3.04 ± 0.78, and 0.98 ± 0.37, respectively (∗∗∗p < 0.001, Student's t-test). Imaging filter:1000 nmLP. Exposure time:300 ms. Excitation wavelength:808 nm. Laser power density: 21.10 mW/cm². Imaging field of view: 10 cm.The type of camera sensor: InGaAs.